Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms

Circulation: Heart Failure

Volumn 4, Issue 4, 2011, Pages 483-495

  Moilanen, Anne Mari ^a   Rysä, Jaana ^a   Mustonen, Erja ^a   Serpi, Raisa ^a   Aro, Jani ^a   Tokola, Heikki ^a   Leskinen, Hanna ^a   Manninen, Aki ^a   Levijoki, Jouko ^b   Vuolteenaho, Olli ^a   Ruskoaho, Heikki ^a  

^a UNIVERSITY OF OULU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Angiogenesis; B type natriuretic peptide; Fibrosis; Gene therapy; Heart failure; Myocardial infarction

Indexed keywords

ANGIOTENSIN II; BETA GALACTOSIDASE; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 3; MESSENGER RNA; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; PHOSFOLAN; PHOSPHOROTHIOIC ACID DERIVATIVE;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; HEART; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; FIBROSIS; GENE THERAPY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; LIGATION; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADENOVIRIDAE; ANGIOTENSIN II; ANIMALS; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; FIBROSIS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; HYPERTENSION; LIGATION; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANOTHIOPHOSPHORUS COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80052808787     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.958033     Document Type: Article

References (53)

1. Heart Disease and Stroke Statistics: 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
3. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365:1877-1889. (Pubitemid 40744967)
4. Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, Liu PP, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghiade M. Acute heart failure syndromes in patients with coronary artery disease: early assessment and treatment. J Am Coll Cardiol. 2009;53:254-263.
5. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996; 31:7-18. (Pubitemid 26093751)
6. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev. 2003;24:341-356. (Pubitemid 36724374)
7. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-142. (Pubitemid 46916959)
8. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handbook Exp Pharmacol. 2009;191:341-366.
9. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491 (Pubitemid 40470642)
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442.
11. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009; 119:1977-2016.
12. Tenhunen O, Soini Y, Ilves M, Rysa J, Tuukkanen J, Serpi R, Pennanen H, Ruskoaho H, Leskinen H. p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. FASEB J. 2006;20:1907-1909.
13. Suo M, Hautala N, Földes G, Szokodi I, Tóth M, Leskinen H, Uusimaa P, Vuolteenaho O, Nemer M, Ruskoaho H. Posttranscriptional control of BNP gene expression in angiotensin II-induced hypertension. Hypertension. 2002;39:803-808. (Pubitemid 34252880)
14. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppa ̈luoto J, Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50:1576-1588. (Pubitemid 39121226)
15. Dorn GW II. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 2009;6:283-291.
16. Yi BA, Wernet O, Chien KR. Pregenerative medicine: developmental paradigms in the biology of cardiovascular regeneration. J Clin Invest. 2010;120:20-28.
17. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205. (Pubitemid 34059525)
18. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-Type natriuretic peptide exerts broad functional opposition to transforming growth factor-{beta} in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453-461. (Pubitemid 38326280)
19. Szokodi I, Kerkela R, Kubin A, Sarman B, Pikkarainen S, Konyi A, Horvath IG, Papp L, Toth M, Skoumal R, Ruskoaho H. Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility. Circulation. 2008;118:1651-1658.
20. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687. (Pubitemid 40261821)
21. Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handbook Exp Pharmacol. 2009;191: 485-506.
22. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello- Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC, Jr. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008;118:1729-1736.
23. Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K, Kangawa K. Natriuretic peptide signaling via guanylyl cyclase (GC)-A: an endogenous protective mechanism of the heart. Curr Cardiol Rev. 2009;5:45-51.
24. Kuhn M. Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handbook Exp Pharmacol. 2009;191:47-69.
25. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello- Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91:1127-1134. (Pubitemid 36076361)
26. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y, Nakao K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004;110:3306-3312. (Pubitemid 39557492)
27. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
28. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94:14730-14735. (Pubitemid 28041442)
29. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M, Nakao K. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97:4239-4424.
30. Lin X, Hänze J, Heese F, Sodmann R, Lang RE. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res. 1995;77: 750-758.
31. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227-234.
32. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K, Imura H. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992;130: 229-239.
33. Tanaka M, Hiroe M, Nishikawa T, Sato T, Marumo F. Cellular localization and structural characterization of natriuretic peptide-expressing ventricular myocytes from patients with dilated cardiomyopathy. J Histochem Cytochem. 1994;42:1207-1214. (Pubitemid 24267608)
34. Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U, Jacoby C, Stypmann J, van Eickels M, Gambaryan S, Hartmann M, Werner M, Wieland T, Schrader J, Baba HA. The natriuretic peptide/guanylyl cyclase-A system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest. 2009;119:2019-2030.
35. Yamahara K, Itoh H, Chun T, Ogawa Y, Yamashita J, Sawada N, Fukunaga Y, Sone M, Yurugi-Kobayashi T, Miyashita K, Tsujimoto H, Kook H, Feil R, Garbers DL, Hofmann F, Nakao K. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A. 2003;100:3404-3409. (Pubitemid 36356596)
36. Pikkarainen S, Tokola H, Majalahti-Palviainen T, Kerkela R, Hautala N, Bhalla SS, Charron F, Nemer M, Vuolteenaho O, Ruskoaho H. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J Biol Chem. 2003;278:23807-23816. (Pubitemid 36830205)
37. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A, Klevitsky R, Vaikunth S, Duncan SA, Aronow BJ, Robbins J, Crombleholm TM, Molkentin JD. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest. 2007;117:3198-3210. (Pubitemid 350096978)
38. Rysä J, Tenhunen O, Serpi R, Soini Y, Nemer M, Leskinen H, Ruskoaho H. GATA-4 is an angiogenic survival factor of the infarcted heart. Circ Heart Fail. 2010;3:440-450.
39. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res. 2003;57:8-19. (Pubitemid 36009431)
40. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol. 2007;171:1431-1440. (Pubitemid 350158305)
41. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117:3176-3179. (Pubitemid 350096973)
42. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 1998;37:279-289. (Pubitemid 28165990)
43. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK, Hajjar RJ. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A. 2004;101:5622-5627. (Pubitemid 38481206)
44. Lompré AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation. 2010;121:822-830.
45. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW II, Kranias EG. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation. 2001; 103:889-896. (Pubitemid 32163890)
46. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31:479-491. (Pubitemid 29121635)
47. Hagemann D, Kuschel M, Kuramochi T, Zhu W, Cheng H, Xiao R. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J Biol Chem. 2000;275:22532-22536. (Pubitemid 30621843)
48. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskamper J, Westermann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R, Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss HP, Hajjar RJ, Poller WC. Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241-1252.
49. Keller M, Gerbes AL, Kulhanek-Heinze S, Gerwig T, Grutzner U, van Rooijen N, Vollmar AM, Kiemer AK. Hepatocyte cytoskeleton during ischemia and reperfusion-influence of ANP-mediated p38 MAPK activation. World J Gastroenterol. 2005;11:7418-7429. (Pubitemid 43126021)
50. Kiemer AK, Weber NC, Fürst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res. 2002;90:874-881. (Pubitemid 34633879)
51. Tenhunen O, Rysä J, Ilves M, Ruskoaho H, Leskinen H. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 MAPK in the heart. Circ Res. 2006;99:485-493. (Pubitemid 44337820)
52. Leskinen H, Rauma-Pinola T, Szokodi I, Kerkelä R, Pikkarainen S, Uusimaa P, Hautala T, Vuolteenaho O, Ruskoaho H. Adaptive or maladaptive response to adenoviral adrenomedullin gene transfer is contextdependent in the heart. J Gene Med. 2008;10:867-877.
53. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, Redfield MM, Simari RD, Lerman A, Cataliotti A, Burnett JC Jr. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009;95:1315-1319.